Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
Oncology drugs are often approved for multiple indications, for which their clinical benefit varies. Aligning a single price to this differing value remains a challenge. This study examines the clinical and economic value, price, and reimbursement of multi-indication cancer drugs across seven countr...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
11 July 2022
|
| In: |
Applied health economics and health policy
Year: 2022, Jahrgang: 20, Heft: 5, Pages: 757-768 |
| ISSN: | 1179-1896 |
| DOI: | 10.1007/s40258-022-00737-w |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s40258-022-00737-w Verlag, kostenfrei, Volltext: https://link.springer.com/content/pdf/10.1007/s40258-022-00737-w.pdf?pdf=button 
|
| Verfasserangaben: | Daniel Tobias Michaeli, Mackenzie Mills, Panos Kanavos |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 186029314X | ||
| 003 | DE-627 | ||
| 005 | 20240307083617.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230926s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40258-022-00737-w |2 doi | |
| 035 | |a (DE-627)186029314X | ||
| 035 | |a (DE-599)KXP186029314X | ||
| 035 | |a (OCoLC)1425216765 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Michaeli, Daniel |d 1997- |e VerfasserIn |0 (DE-588)1277183244 |0 (DE-627)1830345109 |4 aut | |
| 245 | 1 | 0 | |a Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland |c Daniel Tobias Michaeli, Mackenzie Mills, Panos Kanavos |
| 264 | 1 | |c 11 July 2022 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.09.2023 | ||
| 520 | |a Oncology drugs are often approved for multiple indications, for which their clinical benefit varies. Aligning a single price to this differing value remains a challenge. This study examines the clinical and economic value, price, and reimbursement of multi-indication cancer drugs across seven countries, representing different approaches to value assessment, pricing, and coverage decisions: the USA, Germany, France, England, Canada, Australia, and Scotland. | ||
| 700 | 1 | |a Mills, Mackenzie |e VerfasserIn |0 (DE-588)1189338823 |0 (DE-627)1668014785 |4 aut | |
| 700 | 1 | |a Kanavos, Panos |d 1964- |e VerfasserIn |0 (DE-588)13358920X |0 (DE-627)549549137 |0 (DE-576)299954323 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Applied health economics and health policy |d [Erscheinungsort nicht ermittelbar] : Springer International, 2004 |g 20(2022), 5 vom: Sept., Seite 757-768 |h Online-Ressource |w (DE-627)481906118 |w (DE-600)2180637-8 |w (DE-576)313702640 |x 1179-1896 |7 nnas |a Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland |
| 773 | 1 | 8 | |g volume:20 |g year:2022 |g number:5 |g month:09 |g pages:757-768 |g extent:12 |a Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s40258-022-00737-w |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://link.springer.com/content/pdf/10.1007/s40258-022-00737-w.pdf?pdf=button |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230926 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 1277183244 |a Michaeli, Daniel |m 1277183244:Michaeli, Daniel |d 60000 |e 60000PM1277183244 |k 0/60000/ |p 1 |x j | ||
| 999 | |a KXP-PPN186029314X |e 4379032345 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Michaeli","given":"Daniel","display":"Michaeli, Daniel","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Mills, Mackenzie","roleDisplay":"VerfasserIn","role":"aut","family":"Mills","given":"Mackenzie"},{"given":"Panos","family":"Kanavos","role":"aut","display":"Kanavos, Panos","roleDisplay":"VerfasserIn"}],"title":[{"title":"Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland","title_sort":"Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland"}],"recId":"186029314X","language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 26.09.2023"],"name":{"displayForm":["Daniel Tobias Michaeli, Mackenzie Mills, Panos Kanavos"]},"id":{"doi":["10.1007/s40258-022-00737-w"],"eki":["186029314X"]},"origin":[{"dateIssuedDisp":"11 July 2022","dateIssuedKey":"2022"}],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and ScotlandApplied health economics and health policy","note":["Gesehen am 23.04.14"],"language":["eng"],"recId":"481906118","pubHistory":["Nachgewiesen 3.2004 - 5.2006; 6.2008 -"],"part":{"issue":"5","pages":"757-768","year":"2022","extent":"12","text":"20(2022), 5 vom: Sept., Seite 757-768","volume":"20"},"title":[{"title":"Applied health economics and health policy","title_sort":"Applied health economics and health policy"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"2004-","publisher":"Springer International ; Adis International ; Adis","dateIssuedKey":"2004","publisherPlace":"[Erscheinungsort nicht ermittelbar] ; Auckland ; [Erscheinungsort nicht ermittelbar]"}],"id":{"issn":["1179-1896"],"zdb":["2180637-8"],"eki":["481906118"]}}],"physDesc":[{"extent":"12 S."}]} | ||
| SRT | |a MICHAELIDAVALUEANDPR1120 | ||